Phase II study of irinotecan and tegafur gimeracil for NSCLC with EGFR mutation which resistant to EGFR-TKI
Not Applicable
- Conditions
- on-small-cell lung cancer
- Registration Number
- JPRN-UMIN000001800
- Lead Sponsor
- orth Japan Lung Cancer Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
1. Pre-treated with 5-FU related drugs or irinotecan 2. With severe comorbidities 3. With symptomatic brain metastasis 4. Pregnant women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease controll rate at 8 weeks after the initiation of treatment
- Secondary Outcome Measures
Name Time Method